製品番号: HY-B0246

カルバマゼピン

(別名: Carbamazepine; CBZ; NSC 169864)

18 Cited Publications

カスタマーレビュー

Based on 18 publication(s) in Google Scholar

Carbamazepine is an orally active pressure-sensitive sodium ion channel blocker with an IC₅₀ of 131 μM. Carbamazepine blocks voltage gated Na⁺, Ca²⁺, and K⁺ channels, and is also a HDAC inhibitor (IC₅₀: 2 μM). Carbamazepine is an anticonvulsant and can be used for research of epilepsy and neuropathic pain.

商品は「研究用試薬」です。人や動物の医療用・臨床診断用・食品用の製品ではありません。
研究用途以外に使用した場合、当社は一切の責任を負いかねます。

純度: 99.90%
CAS 番号: 298-46-4
分子式: C₁₅H₁₂N₂O
分子量:236.27

保管条件:

Store at room temperature 3 years.

In solvent -80°C, 2 years , -20°C, 1 year

Carbamazepine 構造式

CAS 番号: 298-46-4

容量

価格（税別）

在庫状況

数量

Amount: USD 0.00

* アイテムを追加する前、数量をご選択ください

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

生物活性
- 製品説明
- Cellular Effect
- 体外実験
- 体内実験
- 臨床実験
化学情報
Publications (18)
溶剤 & 溶解度
- 体外
- 体内
純度とドキュメンテーション
参考文献
Help & FAQs
関連分類
Bioz

生物活性

製品説明

Sodium Channel アイソフォーム固有の製品をすべて表示 :

Calcium Channel アイソフォーム固有の製品をすべて表示 :

HDAC アイソフォーム固有の製品をすべて表示 :

Cellular Effect

Cell Line	Type	Value	Description	References
HEK293	IC₅₀	22 μM Compound: 2, carbamazepine	Blockade of human Nav1.7 channel expressed in HEK293 cells by FRET assay Blockade of human Nav1.7 channel expressed in HEK293 cells by FRET assay	[PMID: 18243692]
Hepatocyte	EC₅₀	145 μM Compound: Carbamazepine	Induction of CYP2B6 activity in human donor hepatocytes assessed as hydroxybupropion formation after 48 hrs by LC/MS method Induction of CYP2B6 activity in human donor hepatocytes assessed as hydroxybupropion formation after 48 hrs by LC/MS method	[PMID: 22815312]
Hepatocyte	EC₅₀	26 μM Compound: Carbamazepine	Induction of CYP2B6 mRNA expression in human donor hepatocytes after 48 hrs by real-time PCR method Induction of CYP2B6 mRNA expression in human donor hepatocytes after 48 hrs by real-time PCR method	[PMID: 22815312]
ScN2a	EC₅₀	>10 μM Compound: Carbamazepine	Half maximal inhibition of Prion protein PrPsc formation was assayed in ScN2a cells Half maximal inhibition of Prion protein PrPsc formation was assayed in ScN2a cells	[PMID: 12904059]
Sf21	IC₅₀	>1000 μM Compound: Carbamazepine	Inhibition of human BSEP expressed in plasma membrane vesicles of Sf21 cells assessed as inhibition of ATP-dependent [3H]taurocholate uptake Inhibition of human BSEP expressed in plasma membrane vesicles of Sf21 cells assessed as inhibition of ATP-dependent [3H]taurocholate uptake	[PMID: 21965623]
Sf21	IC₅₀	>1000 μM Compound: Carbamazepine	Inhibition of Sprague-Dawley rat Bsep expressed in plasma membrane vesicles of Sf21 cells assessed as inhibition of ATP-dependent [3H]taurocholate uptake Inhibition of Sprague-Dawley rat Bsep expressed in plasma membrane vesicles of Sf21 cells assessed as inhibition of ATP-dependent [3H]taurocholate uptake	[PMID: 21965623]

体外実験

Carbamazepine (0-500 μM, 10 days) inhibits pre-adipocyte differentiation (10 days) and triglyceride accumulation (7 days) in 3T3-L1, 3T3-F442A and T37i cells^[4].
Carbamazepine (5-20 μM, 15 min before LPS) inhibits LPS-induced production of NO and iNOS protein, and phosphorylation of Akt in microglial (BV-2) cells^[5].
Carbamazepine (20 μM, 15 min before LPS) inhibits LPS-induced COX-2 expression and TNF-α production in microglial (BV-2) cells^[5].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Western Blot Analysis^[4]

Cell Line:

3T3-L1 pre-adipocytes
Concentration:

0-500 μM
Incubation Time:

10 days
Result:

Decreased PPAR-γ and C/EPB-α protein levels.
Increased ERK 1/2 phosphorylation after a 10 min exposure, and also increased p38 MAPK phosphorylation.

体内実験

Carbamazepine (250 mg/kg, p.o.) promotes liver regeneration and survival in partial hepatectomy (PHx) treated mice^[6].
Carbamazepine (0.25%-0.75% for ICR mice, 0.5% and 0.75% for C57bl/6 mice with, in food (w/w)) shows mood-stabilising effects in mice^[7].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:

70% Partial hepatectomy treated mice^[6]
Dosage:

250 mg/kg
Administration:

p.o.
Result:

Recoverd liver to body weight ratio.
Increased the number of BrdU-positive nuclei, Increased PCNA protein.
Increased mRNA levels of ccne2 and ccna2.

臨床実験

NCT Number	Sponsor	Condition	Start Date	Phase A549
NCT01329991	Plexxikon\|		2011-05	PHASE1

化学情報

CAS 番号 298-46-4
性状 Solid
分子量 236.27
分子式 C₁₅H₁₂N₂O
Color White to off-white
SMILES

O=C(N1C2=CC=CC=C2C=CC3=CC=CC=C31)N
別名

Carbamazepine; CBZ; NSC 169864
輸送条件

Room temperature in continental US; may vary elsewhere.

保管条件

Store at room temperature 3 years

In solvent	-80°C	2 years
	-20°C	1 year

Publications (18)

All Cell Proliferation/Viability AssayIn Vivo Efficacy StudyBio/Physico-chemical AssayPK/PD Analysis

Sort by:

Journal Impact Factor

Adv Funct Mater

2025 Nov 3.

Carbamazepine purchased from MedChemExpress. Usage Cited in: Adv Funct Mater. 2025 Nov 3.

Carbamazepine (CBZ; 1–50 µg/mL; 24 h) exhibited extremely low cytotoxicity in SH-SY5Y cells at concentrations below 12.5 µg/mL. However, at a concentration of 50 µg/mL, cell viability decreased significantly to below 80%.
Autophagy

Stimulating the autophagic-lysosomal axis enhances host defense against fungal infection in a zebrafish model of invasive Aspergillosis. [Abstract]

2023 Jan;19(1):324-337. PMID: 35775203

Carbamazepine purchased from MedChemExpress. Usage Cited in: Autophagy. 2023 Jan;19(1):324-337. [Abstract]

Survival curves of zebrafish embryos infected with A. fumigatus ∆Ku80 and exposed via waterborne treatment to 100 μM Carbamazepine (Mtor-independent induction of autophagy via the inositol pathway), or DMSO as a vehicle control at the same v:v. The results showed that the autophagy-inducing treatment (Carbamazepine) consistently enhanced host survival during A. fumigatus infection compared to the DMSO control.
Nat Commun

Structural mapping of Nav1.7 antagonists. [Abstract]

2023 Jun 3;14(1):3224. PMID: 37270609
Theranostics

ATF4 destabilizes RET through nonclassical GRP78 inhibition to enhance chemosensitivity to bortezomib in human osteosarcoma. [Abstract]

2019 Aug 14;9(21):6334-6353. PMID: 31534554
J Pharm Anal

Discovery of E0199: A novel compound targeting both peripheral NaV and KV7 channels to alleviate neuropathic pain. [Abstract]

2025 Jan;15(1):101132. PMID: 39906690

Carbamazepine purchased from MedChemExpress. Usage Cited in: J Pharm Anal. 2025 Jan;15(1):101132. [Abstract]

Carbamazepine (CBZ, 10 μM) exhibited an inhibition rate of 39.00% on Na_V1.7 channels and 28.02% on Na_V1.8 channels.
Emerg Contam

2026 Feb 23.
Chin Med

Identification of anti-fibrotic compounds from Piper longum L via hollow fiber cell fishing and high-performance liquid chromatography with in vivo and in vitro validation. [Abstract]

2025 Aug 19;20(1):127. PMID: 40830877
Commun Biol

Permethrin induces epileptic susceptibility via activation of Na+ channels and rise in glutamate. [Abstract]

2025 Nov 24;8(1):1644. PMID: 41286411
Cell Rep Methods

RECOVER identifies synergistic drug combinations in vitro through sequential model optimization. [Abstract]

2023 Oct 23;3(10):100599. PMID: 37797618
Int Immunopharmacol

Lidocaine inhibits influenza a virus replication by up-regulating IFNα4 via TBK1-IRF7 and JNK-AP1 signaling pathways. [Abstract]

2023 Feb:115:109706. PMID: 36638664
Biotechnol Bioeng

An integrated biomimetic array chip for establishment of collagen-based 3D primary human hepatocyte model for prediction of clinical drug-induced liver injury. [Abstract]

2021 Dec;118(12):4687-4698. PMID: 34478150
J Integr Neurosci

The Neuroprotective Role of a Caspase-1 Inhibitor Against Apoptosis via Inhibition of Glial Hyperactivation in a Mouse Model of Epilepsy. [Abstract]

2026 May 9;25(5):49777. PMID: 42216646
Pharmacol Res Perspect

Effects of membrane transport activity and cell metabolism on the unbound drug concentrations in the skeletal muscle and liver of drugs: A microdialysis study in rats. [Abstract]

2021 Oct;9(5):e00879. PMID: 34628723

Carbamazepine purchased from MedChemExpress. Usage Cited in: Pharmacol Res Perspect. 2021 Oct;9(5):e00879. [Abstract]

Pharmacokinetic parameters of the 14 compounds following an IV single bolus (n = 3; mean ± SD) (n = 3, mean ± SD).
Pharmacol Res Perspect

Applicability of free drug hypothesis to drugs with good membrane permeability that are not efflux transporter substrates: A microdialysis study in rats. [Abstract]

2020 Apr;8(2):e00575. PMID: 32266794
World J Methodol

Anticonvulsant potential of rosuvastatin in combination with carbamazepine and valproate in animal models of epilepsy. [Abstract]

2025 Jun 20;15(2):99580. PMID: 40548212

Carbamazepine purchased from MedChemExpress. Usage Cited in: World J Methodol. 2025 Jun 20;15(2):99580. [Abstract]

Carbamazepine (4–8 mg/kg) inhibited tonic hindlimb extension (THLE) in mice, demonstrating a significant anticonvulsant protective effect.
University of Glasgow

2023.
Biomed Pharmacother

Remdesivir inhibits the progression of glioblastoma by enhancing endoplasmic reticulum stress. [Abstract]

2023 Jan:157:114037. PMID: 36427388
Chemosphere

Mass-balance-model-based evaluation of sewage treatment plant contribution to residual pharmaceuticals in environmental waters. [Abstract]

2019 Jun:225:378-387. PMID: 30884299

溶剤 & 溶解度

体外:

DMSO : 50 mg/mL (211.62 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

H₂O : < 0.1 mg/mL (insoluble)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

4.2324 mL

21.1622 mL

42.3245 mL

5 mM

0.8465 mL

4.2324 mL

8.4649 mL

10 mM

0.4232 mL

2.1162 mL

4.2324 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

モル濃度計算機

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

濃度濃度

体積体積

分子量分子量

希釈計算機

濃度 _(開始) × 体積 _(開始) = 濃度 _(終了) × 体積 _(終了)

濃度 _(開始) 濃度 _(開始)

体積 _(開始) 体積 _(開始)

濃度 _(終了) 濃度 _(終了)

体積 _(終了) 体積 _(終了)

体内:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline

Solubility: ≥ 2.5 mg/mL (10.58 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)

Solubility: ≥ 2.5 mg/mL (10.58 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

Protocol 3

Add each solvent one by one: 10% DMSO 90% Corn Oil

Solubility: ≥ 2.5 mg/mL (10.58 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL Corn oil, and mix evenly.

Working Solution

For the following dissolution methods, please prepare the working solution directly:

It is recommended to prepare fresh solutions and use them promptly within a short period of time.

The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 50% PEG300 50% Saline

Solubility: 25 mg/mL (105.81 mM); Clear solution; Need ultrasonic

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

純度とドキュメンテーション

バッチを選択:

純度: 99.98%

Assay: 99.98%

ee.: 99.98%

データシート (287 KB)
SDS (558 KB)
- English - EN (558 KB)
- Français - FR (558 KB)
- Deutsch - DE (558 KB)
- Norwegian - NO (558 KB)
- Español - ES (558 KB)
- Swedish - SV (558 KB)
- Italian - IT (558 KB)
- Korean - KR (558 KB)
- Portuguese - PT (558 KB)
COA (2659 KB)
元素分析報告書 (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
取扱説明書 (2659 KB)

参考文献

[1]. Willow, M. and W.A. Catterall, Inhibition of binding of [3H]batrachotoxinin A 20-alpha-benzoate to sodium channels by the anticonvulsant drugs diphenylhydantoin and carbamazepine. Mol Pharmacol, 1982. 22(3): p. 627-35. [Content Brief]

[2]. Okada, M., et al., Biphasic effects of carbamazepine on the dopaminergic system in rat striatum and hippocampus. Epilepsy Res, 1997. 28(2): p. 143-53. [Content Brief]

[3]. Beutler AS, et al. Carbamazepine is an inhibitor of histone deacetylases. Life Sci. 2005 May 13;76(26):3107-15. [Content Brief]

[4]. Turpin E, et al. Carbamazepine directly inhibits adipocyte differentiation through activation of the ERK 1/2 pathway. Br J Pharmacol. 2013 Jan;168(1):139-50. [Content Brief]

[5]. Wang CH, et al. Carbamazepine attenuates inducible nitric oxide synthase expression through Akt inhibition in activated microglial cells. Pharm Biol. 2014 Nov;52(11):1451-9. [Content Brief]

[6]. Kawaguchi T, et al. Carbamazepine promotes liver regeneration and survival in mice. J Hepatol. 2013 Dec;59(6):1239-45. [Content Brief]

[7]. Kara NZ, et al. Chronic oral carbamazepine treatment elicits mood-stabilising effects in mice. Acta Neuropsychiatr. 2014 Feb;26(1):29-34. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	4.2324 mL	21.1622 mL	42.3245 mL	105.8111 mL
	5 mM	0.8465 mL	4.2324 mL	8.4649 mL	21.1622 mL
	10 mM	0.4232 mL	2.1162 mL	4.2324 mL	10.5811 mL
	15 mM	0.2822 mL	1.4108 mL	2.8216 mL	7.0541 mL
	20 mM	0.2116 mL	1.0581 mL	2.1162 mL	5.2906 mL
	25 mM	0.1693 mL	0.8465 mL	1.6930 mL	4.2324 mL
	30 mM	0.1411 mL	0.7054 mL	1.4108 mL	3.5270 mL
	40 mM	0.1058 mL	0.5291 mL	1.0581 mL	2.6453 mL
	50 mM	0.0846 mL	0.4232 mL	0.8465 mL	2.1162 mL
	60 mM	0.0705 mL	0.3527 mL	0.7054 mL	1.7635 mL
	80 mM	0.0529 mL	0.2645 mL	0.5291 mL	1.3226 mL
	100 mM	0.0423 mL	0.2116 mL	0.4232 mL	1.0581 mL

Keywords

Carbamazepine

18 Cited Publications

100 mg お問い合わせ

Subscribe to the

MedChemExpress

Newsletter

製品名:
製品番号:
数量:
日本の代理先をお選びください:

製品名:
CAS 番号:
生物種:
純度:
数量:

カルバマゼピン

Bioactive Compound Library Max

Bioactive Compound Library

Anti-Infection Compound Library

Cell Cycle/DNA Damage Compound Library

Epigenetics Compound Library

Membrane Transporter/Ion Channel Compound Library

Neuronal Signaling Compound Library

FDA-Approved Drug Library

Histone Modification Research Compound Library

CNS-Penetrant Compound Library

Autophagy Compound Library

Anti-Aging Compound Library

Drug Repurposing Compound Library

Reprogramming Compound Library

Oxygen Sensing Compound Library

Anti-COVID-19 Compound Library

NMPA-Approved Drug Library

Orally Active Compound Library

FDA Approved & Pharmacopeial Drug Library

Anti-Alzheimer's Disease Compound Library

Neuroprotective Compound Library

Anti-Breast Cancer Compound Library

Drug-Induced Liver Injury (DILI) Compound Library

Anti-Pancreatic Cancer Compound Library

Anti-Blood Cancer Compound Library

Neurodegenerative Disease-related Compound Library

Mitochondria-Targeted Compound Library

Targeted Diversity Library

Anti-Liver Cancer Compound Library

Rare Diseases Drug Library

Pediatric Drug Library

Calcium Channel Blocker Library

Sodium Channel Blocker Library

Potassium Channel Compound Library

Human Metabolite Library

Osteogenesis Compound Library

Off-patent Drug Library

Mitochondrial Protection Compound Library

Antihypertensive Compound Library

Membrane Protein-targeted Compound Library

Membrane Receptor-targeted Compound Library

Cell Death Library

Ion Channel Compound Library

Anti-Hematopathy Compound Library

Multi-Target Compound Library

Mitophagy Compound Library

MCE Bioactive Compound Library

Drug Repurposing Compound Library Plus

FDA-Approved Drug Library Plus

FDA-Approved Drug Library Mini

Anti-Brain Cancer Compound Library

Non-Alcoholic Fatty Liver Disease (NAFLD) Compound Library

High-Throughput Bioactive Compound Library

Mass Spectrometry Human Metabolite Library

Cardiotoxic Compound Library

Nephrotoxicity Compound Library

High-Efficiency Gene Editing Compound Library

Lactylation Compound Library

MedChemExpress（MCE）の使用を引用している文献 Carbamazepine

Sodium Channel アイソフォーム固有の製品をすべて表示

Calcium Channel アイソフォーム固有の製品をすべて表示

HDAC アイソフォーム固有の製品をすべて表示

生物活性

化学情報

Publications (18)

溶剤 & 溶解度

純度とドキュメンテーション

参考文献

Help & FAQs

Complete Stock Solution Preparation Table

Carbamazepine 関連分類

HY-B0246 関連分類